JPH0639384B2 - Composition for preventive treatment of pressure ulcer - Google Patents
Composition for preventive treatment of pressure ulcerInfo
- Publication number
- JPH0639384B2 JPH0639384B2 JP9784786A JP9784786A JPH0639384B2 JP H0639384 B2 JPH0639384 B2 JP H0639384B2 JP 9784786 A JP9784786 A JP 9784786A JP 9784786 A JP9784786 A JP 9784786A JP H0639384 B2 JPH0639384 B2 JP H0639384B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- present
- starch
- pressure ulcer
- etherified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Description
【発明の詳細な説明】 〔産業上の利用分野〕 本発明は新規褥瘡（床ずれ）の予防治療用組成物に関す
るものである。TECHNICAL FIELD The present invention relates to a novel composition for preventing and treating pressure ulcer (bed sores).
従来褥瘡の予防・治療には圧迫が一部分に加わらないよ
うに体位の変換や初期や軽度のものは皮膚の清拭及びコ
ンベツク軟膏の外用、また瘡の乾燥のためには水溶性軟
膏などの使用が行われている（今日の治療指針、１９８
６年版Ｐ６１３〜６１４）。Conventionally, in the prevention and treatment of pressure ulcers, the posture is changed so that pressure is not applied to a part of the body, and the initial and mild ones are used for cleaning the skin and external application of a convex ointment, and for the drying of acne, a water-soluble ointment is used. Is being carried out (Today's treatment guidelines, 198
6th edition P613-614).
しかしながら、長期臥床患者の場合、十分な看護が行わ
れないと、褥瘡の発生はほとんどさけられず、軟膏等の
使用によっても必ずしも満足すべき結果は得られていな
いのが現状である。本発明者は本発明の組成物が褥瘡の
予防治療に顕著な効果を有することを見い出し本発明を
完成した。However, in the case of long-term bed rest patients, the occurrence of pressure ulcers is almost unavoidable unless adequate nursing care is performed, and the current situation is that satisfactory results have not been obtained even by using an ointment or the like. The present inventors have found that the composition of the present invention has a significant effect on the prevention and treatment of pressure ulcers and completed the present invention.
本発明は、エーテル化澱粉を主成分として含有すること
を特徴とする褥瘡の予防治療用組成物に関するものであ
る。The present invention relates to a preventive and therapeutic composition for pressure ulcer, which comprises etherified starch as a main component.
本発明におけるエーテル化澱粉とは、澱粉のヒドロキシ
ル基を常法によりエーテル化したものであればよいが、
澱粉にエピクロルヒドリンを作用させて得られるエーテ
ル化澱粉は好ましい。The etherified starch in the present invention may be one obtained by etherifying the hydroxyl group of starch by a conventional method,
Etherified starch obtained by allowing epichlorohydrin to act on starch is preferred.
澱粉のエーテル化率は特に制限はないが、通常澱粉の反
応型水酸基に対して、０．５〜４０％好ましくは１〜１
０％、より好ましくは１．５〜５％であり、おおよそ２
〜４％程度が最も適当である。The etherification rate of starch is not particularly limited, but is usually 0.5 to 40%, preferably 1 to 1 relative to the reactive hydroxyl group of starch.
0%, more preferably 1.5-5%, approximately 2
About 4% is the most suitable.
澱粉の種類は特に問わないが、とうもろこし澱粉が好ま
しい。The type of starch is not particularly limited, but corn starch is preferred.
本発明の組成物におけるエーテル化澱粉の割合は、主成
分として全体に対して４０％（重量）以上であればよ
く、通常５０％以上であり、好ましくは６０％以上より
好ましくは７０％以上であり、８０％ないしは９０％以
上の場合最も好ましい結果が得られる。The proportion of the etherified starch in the composition of the present invention may be 40% (weight) or more as a main component with respect to the whole, and is usually 50% or more, preferably 60% or more, more preferably 70% or more. And the most preferable result is obtained when it is 80% to 90% or more.
本発明の組成物は使用目的などに応じ、エーテル化澱粉
だけでもまたそれ以外の成分、例えば薬効成分や医薬用
助剤、担体などが含まれてもよい。例えば初期褥瘡や予
防に使用する際にはエーテル化澱粉だけでもよく、より
進んだ褥瘡の治療を目的とする場合には、抗菌剤などを
配合して使用するのが好ましい。The composition of the present invention may contain only etherified starch or other components such as medicinal components, medicinal auxiliaries and carriers depending on the purpose of use. For example, when used for early stage pressure ulcer or prevention, only etherified starch may be used, and for the purpose of more advanced treatment for pressure ulcer, it is preferable to use an antibacterial agent in combination.
また組成物の防湿などの観点からマグネシウム化合物を
含むのが好ましく、その量は０．５〜５０％（重量）程
度の範囲で十分である。例えば酸化マグネシウムの場合
０．５〜１０％、好ましくは１〜５％程度であり、炭酸
マグネシウムの場合１〜５０％、好ましくは２０〜４０
％程度である。Further, it is preferable that the composition contains a magnesium compound from the viewpoint of moisture resistance of the composition, and the amount thereof is preferably in the range of about 0.5 to 50% (weight). For example, in the case of magnesium oxide, it is 0.5 to 10%, preferably 1 to 5%, and in the case of magnesium carbonate, 1 to 50%, preferably 20 to 40%.
%.
本発明の組成物の好ましい組成を示すと次の通りであ
る。The preferred composition of the composition of the present invention is as follows.
エーテル化澱粉約５０〜９９．５％より好ましくは約８
０〜９９％、抗菌剤その他助剤、担体など約５０〜０．
５％、より好ましくは約２０〜１％。Etherified starch from about 50 to 99.5%, more preferably about 8.
0 to 99%, antibacterial agents and other auxiliaries, carriers and the like about 50 to 0.
5%, more preferably about 20-1%.
本発明の組成物は通常粉末状で使用するのが好ましく、
エーテル化澱粉の粒子の大きさは全粒子が１００ミクロ
ン以下、好ましくは５０ミクロン以下で、平均粒子径
が、４０ミクロン以下、より好ましくは３０ミクロン以
下、特に２０ミクロン〜５ミクロンが好ましい。また粒
子の形は鋭角のない丸味をもつ粒子であることが好まし
い。The composition of the present invention is usually preferably used in powder form,
The particle size of the etherified starch is 100 micron or less, preferably 50 micron or less, and the average particle size is 40 micron or less, more preferably 30 micron or less, and particularly preferably 20 to 5 micron. Further, the shape of the particles is preferably particles having a roundness with no acute angle.
本発明の組成物を用いて褥瘡の予防治療を行うには本発
明の組成物を褥瘡の発生の兆候を見えた個所もしくは褥
瘡部に散布塗布すればよい。In order to prevent and treat pressure ulcers using the composition of the present invention, the composition of the present invention may be applied by spraying to a place or a pressure ulcer site where signs of the development of pressure ulcer are visible.
本発明の組成物に配合してもよい抗菌剤としては例えば
硫酸フラジオマイシン、硫酸カナマイシン、塩酸テトラ
サイクリンなどがあげられる。Examples of the antibacterial agent that may be added to the composition of the present invention include fradiomycin sulfate, kanamycin sulfate, and tetracycline hydrochloride.
また助剤、担体などとしては本発明の組成物に悪影響を
与えないものであれば医薬用に使用されているものは何
でもさしつかえなく、例えば助剤としては酸化マグネシ
ウム、薬剤の安定化剤としては例えば酒石酸、クエン酸
などの有機酸、アミノ酸類などがあげられ、担体として
は澱粉、糖類などがあげられる。Further, as the auxiliaries, carriers, etc., any of those used for medicine may be used as long as they do not adversely affect the composition of the present invention, for example, magnesium oxide as the auxiliaries, and a stabilizer for the drug. Examples thereof include organic acids such as tartaric acid and citric acid, amino acids and the like, and examples of carriers include starch and sugars.
本発明のエーテル化澱粉は例えばとうもろこし澱粉１重
量部に対し、エピクロルヒドリン０．２〜２０重量％反
応させると、おおよそデンプンの反応性ヒドロキシル基
の０．５〜４０％がエーテル化されたものが得られる。When the etherified starch of the present invention is reacted with, for example, 1 part by weight of corn starch in an amount of 0.2 to 20% by weight of epichlorohydrin, about 0.5 to 40% of reactive hydroxyl groups of starch are obtained by etherification. To be
本発明のエーテル化澱粉の製造例 とうもろこし澱粉（日本食品加工株式会社製、粒径９−
１８ミクロン）２２５ｇを２２５ml水に分散し、エピク
ロルヒドリン５．７ｇを緩徐に撹拌しながら滴下する。
次に水酸化ナトリウム７．５ｇ及び硫酸ナトリウム３６
ｇを水１２０mlに溶解したアルカリ性液を撹拌しながら
徐々に時間をかけて滴下する。Example of production of etherified starch of the present invention Corn starch (manufactured by Japan Food Processing Co., Ltd., particle size 9-
225 g of 18 micron) are dispersed in 225 ml of water, and 5.7 g of epichlorohydrin is added dropwise with gentle stirring.
Then 7.5 g of sodium hydroxide and 36 of sodium sulfate
An alkaline solution prepared by dissolving g in 120 ml of water is gradually added dropwise with stirring over a period of time.
滴下後、稀塩酸で中和し、過脱水した後、エタノール
溶液に分散、もしくはエタノールで洗浄、乾燥すること
により得ることができる。After the dropping, it can be obtained by neutralizing with dilute hydrochloric acid, super dehydrating, dispersing in an ethanol solution, or washing with ethanol and drying.
このようにして得られたエーテル化澱粉はエーテル化率
がデンプンの反応性水酸基のおおよそ３％程度がエーテ
ル化されている。The etherified starch thus obtained has an etherification rate of about 3% of the reactive hydroxyl groups of starch being etherified.
粒子は鋭角をもたない円味をもったもので粒子径は２０
ミクロン以下であった。The particles have a round shape with no sharp angle and the particle size is 20.
It was less than micron.
本発明の組成物はベビーパウダー やシツカロール に
比して著しく吸湿性が高く、かつ滑性もよいことから褥
瘡の予防治療に好い結果を示すものと考えられる。 The composition of the present invention is baby powder And Shitsuka Roll To
Relatively high hygroscopicity and good slipperiness
It is considered to show favorable results for preventive treatment of acne.
本発明の組成物の吸湿性は例えば後記実施例１の組成物
の場合、２５℃湿度９３％の雰囲気下に８日おく場合吸
温による重量増加はおおよそ２２％程度に達する。それ
に対し、ベビーパウダー の場合同一条件でその重量増
加は０．３〜０．４％にすぎず、シツカロール の場
合、同一条件下で重量増加は０．９〜１．０％にすぎな
い。The hygroscopicity of the composition of the present invention is, for example, the composition of Example 1 described later.
In case of 8 days in a 25 ° C / 93% humidity atmosphere
The weight increase due to temperature reaches approximately 22%. It
Against baby powder In the case of
Addition is only 0.3-0.4%, Sitka roll Place
Under the same conditions, the weight gain is only 0.9-1.0%
Yes.
また本発明で使用するエーテル化澱粉は肉芽の形成など
もなく褥瘡の治療予防に非常に適する。Moreover, the etherified starch used in the present invention is very suitable for the treatment and prevention of pressure ulcer without the formation of granulation.
即ち、本発明で使用するエーテル化澱粉を０．８ｇをイ
ヌの腹腔内に散布し、肉芽の形成による臓器のゆ着等の
異常の発生の有無を調査したところ、エーテル化澱粉は
体内に自然吸収され、臓器のゆ着等による異常は全く認
められなかった。That is, 0.8 g of the etherified starch used in the present invention was sprayed into the abdominal cavity of dogs, and the presence or absence of abnormalities such as adhesion of organs due to granulation formation was investigated. Absorbed, and no abnormalities such as adhesion of organs were observed.
対照として行ったタルクの場合には０．１５ｇの散布で
復腔内諸臓器に明らかに強いゆ着が見られた。In the case of talc, which was used as a control, 0.15 g of the talc was sprayed, and obviously strong adhesion was observed in the various organs in the reintroduction cavity.
臨床例 入院後３０日経過の成人男子（年令７３才）の背部に皮
膚が赤くなり褥瘡の徴候が現われたので実施例１の本発
明組成物約２ｇを患部に散布したところ、ジクジクしは
じめた部位もきれいに乾き、以後進行も止まった。その
後ほぼ毎日患者の褥瘡の徴候のあらわれた部位に同様に
約１〜２ｇ散布することにより入院後４カ月経過しても
褥瘡の発生は認められなかった。また本品散布による副
作用も何ら認められなかった。Clinical Example An adult male (aged 73 years old) 30 days after admission had red skin and showed signs of pressure ulcer. Therefore, when about 2 g of the composition of the present invention of Example 1 was applied to the affected area, it began to be jizzed. The parts that were dry also dried cleanly, and the progress stopped. After that, approximately 1 to 2 g was similarly sprayed on the site of the patient where signs of pressure sore appeared almost every day, and no occurrence of pressure sore was observed even 4 months after admission. In addition, no side effects due to the application of this product were observed.
次に実施例により本発明を具体的に説明する。Next, the present invention will be specifically described with reference to examples.
実施例１ エーテル化とうもろこし澱粉（前記製造例で得たもの）
……９８部（重量） 酸化マグネシウム…… ２部（ 〃 ） を十分に撹拌混合して本発明の組成物を得た。Example 1 Etherified corn starch (obtained in the above production example)
...... 98 parts (weight) Magnesium oxide ...... 2 parts (〃) were sufficiently mixed by stirring to obtain a composition of the present invention.
実施例２ エーテル化とうもろこし澱粉（エピクロルヒドリンでの
エーテル化率約５％）……６０部 酸化マグネシウム……３０部 フラジオマイシン……１０部 を十分撹拌混合して、本発明の組成物を得た。Example 2 Etherified corn starch (etherification ratio with epichlorohydrin: about 5%) .. 60 parts Magnesium oxide..30 parts Fradiomycin..10 parts were sufficiently mixed by stirring to obtain a composition of the present invention.
Claims (1)
とを特徴とする褥瘡の予防治療用組成物1. A composition for preventing and treating pressure ulcer, which comprises etherified starch as a main component.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9784786A JPH0639384B2 (en) | 1986-04-30 | 1986-04-30 | Composition for preventive treatment of pressure ulcer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9784786A JPH0639384B2 (en) | 1986-04-30 | 1986-04-30 | Composition for preventive treatment of pressure ulcer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62255427A JPS62255427A (en) | 1987-11-07 |
| JPH0639384B2 true JPH0639384B2 (en) | 1994-05-25 |
Family
ID=14203122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9784786A Expired - Lifetime JPH0639384B2 (en) | 1986-04-30 | 1986-04-30 | Composition for preventive treatment of pressure ulcer |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0639384B2 (en) |
-
1986
- 1986-04-30 JP JP9784786A patent/JPH0639384B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62255427A (en) | 1987-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5081157A (en) | Compositions and in situ methods for forming films on body tissue | |
| US5081158A (en) | Compositions and in situ methods for forming films on body tissue | |
| US5147648A (en) | Method of improving the adhesiveness of gels to mucosae | |
| KR940011240B1 (en) | Pharmaceutical composition for forming films on body tissue | |
| KR930003117B1 (en) | Uses of sulphated sugars | |
| EP2775838B1 (en) | Aqueous antimicrobial composition containing coniferous resin acids | |
| JPH03505448A (en) | Delayed release formulation | |
| CH666405A5 (en) | SOLID, DURABLE PHARMACEUTICAL FORMS WITH ELASTIC FILM COVER. | |
| US6495531B2 (en) | Use of glucosamine and glucosamine derivatives for quick alleviation of itching or localized pain | |
| US5879717A (en) | Wound healing compositions containing iodine and sucrose | |
| JPH08502030A (en) | Biocidal composition containing mustard seed plant extract | |
| DE69733752T2 (en) | DRUGS CONTAINING OXAPROCINE SODIUM SALT, CALIUM SALT, OR TRIS (HYDROXYMETHYL) AMINOMETHANE SALT | |
| CN111632188A (en) | Seaweed polysaccharide composite biological matrix dressing and preparation method thereof | |
| EP0382210B1 (en) | The use of deacetylated chitin for preparing a medicament for the treatment of inflammatory skin diseases | |
| CN101023961B (en) | Medicine composition containing sodium hyaluronate and zinc salt | |
| JPH039885B2 (en) | ||
| JPH0639384B2 (en) | Composition for preventive treatment of pressure ulcer | |
| JPS6121527B2 (en) | ||
| JP2000038342A (en) | Pharmaceutical preparation for restoring bedsore and damaged skin | |
| JPH07507303A (en) | Pharmaceutical powder composition containing a nonionic cellulose ether derivative and a chitin-derived polymer | |
| CN107595819B (en) | A kind of Nano diamond modified liquid adhesive bandage and preparation method thereof | |
| JPH09227387A (en) | Drug externally using for treatment of atopic dermatitis | |
| JPH09169655A (en) | Powder for external use for dermatic ulcer | |
| EP3087990B1 (en) | Gel-forming powder comprising sulfamonomethoxine and chitosan for treating wounds | |
| US3154546A (en) | Methenamine undecylenate and method of preparation |